Register for a Live Webinar on Histotripsy

Skip to content

HistoSonics_Romance_Billboard01_Clipped-1-1

LIVE WEBINAR

Histotripsy for Liver Tumors: Current Experience and Considerations for Medical Oncologists

Current treatment landscape and unmet needs for patients with liver tumors
Current evidence and ongoing research and trials
Patient consideration for histotripsy referrals
Building a multidisciplinary referral pathway
Interactive faculty discussion and extended Q&A

🗓️Thursday, September 24
🕔5PM CT (6PM ET / 3PM PT)
🖥️Teams Webinar

SPEAKERS

Kristen Spencer, MD, Medical Oncologist | NYU
Brock Hewitt, MD, Hepatobiliary and Pancreatic Surgeon | NYU

34Days

05Hours

05Minutes

38Seconds

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

LIVE WEBINAR

Histotripsy for Liver Tumors: Current Experience and Considerations for Medical Oncologists

🗓️Thursday, September 24🕔5PM CT (6PM ET / 3PM PT)🖥️Teams Webinar

SPEAKERS

🗓️Thursday, September 24
🕔5PM CT (6PM ET / 3PM PT)
🖥️Teams Webinar